Opus Genetics, Inc. (IRD)
4.65
+0.19
(+4.26%)
USD |
NASDAQ |
Oct 09, 16:00
4.68
+0.03
(+0.65%)
After-Hours: 20:00
Opus Genetics Price : 4.65 for Oct. 9, 2026
Price Chart
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 09, 2026 | 4.46 | 4.74 | 4.45 | 4.65 | 1.257M |
| Oct 08, 2026 | 4.41 | 4.48 | 4.245 | 4.46 | 1.346M |
| Oct 07, 2026 | 4.35 | 4.66 | 4.25 | 4.41 | 1.841M |
| Oct 06, 2026 | 4.465 | 4.48 | 4.185 | 4.38 | 2.537M |
| Oct 05, 2026 | 4.57 | 4.64 | 4.34 | 4.38 | 2.538M |
| Oct 02, 2026 | 4.56 | 4.67 | 4.445 | 4.58 | 1.791M |
| Oct 01, 2026 | 4.89 | 4.91 | 4.51 | 4.51 | 1.874M |
| Sep 30, 2026 | 4.96 | 5.32 | 4.83 | 4.84 | 2.458M |
| Sep 29, 2026 | 5.07 | 5.15 | 4.80 | 4.955 | 1.526M |
| Sep 28, 2026 | 4.75 | 5.14 | 4.625 | 5.05 | 1.162M |
| Sep 25, 2026 | 4.89 | 4.93 | 4.70 | 4.76 | 1.245M |
| Sep 24, 2026 | 4.76 | 4.955 | 4.60 | 4.87 | 1.831M |
| Sep 23, 2026 | 5.14 | 5.155 | 4.645 | 4.83 | 3.056M |
| Sep 22, 2026 | 5.20 | 5.30 | 5.04 | 5.16 | 1.173M |
| Sep 21, 2026 | 5.17 | 5.55 | 5.17 | 5.22 | 1.981M |
| Sep 18, 2026 | 5.29 | 5.339 | 5.11 | 5.18 | 5.543M |
| Sep 17, 2026 | 5.46 | 5.62 | 5.23 | 5.28 | 1.532M |
| Sep 16, 2026 | 5.80 | 5.80 | 5.345 | 5.41 | 2.335M |
| Sep 15, 2026 | 5.94 | 5.95 | 5.671 | 5.82 | 1.993M |
| Sep 14, 2026 | 6.02 | 6.22 | 5.795 | 5.97 | 2.552M |
| Sep 11, 2026 | 6.16 | 6.576 | 5.77 | 6.04 | 4.658M |
| Sep 10, 2026 | 5.87 | 6.24 | 5.40 | 6.07 | 6.537M |
| Sep 09, 2026 | 5.31 | 7.07 | 5.31 | 5.73 | 54.32M |
| Sep 08, 2026 | 4.532 | 4.623 | 4.305 | 4.34 | 2.269M |
| Sep 04, 2026 | 4.53 | 4.80 | 4.40 | 4.67 | 2.240M |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Rezolute, Inc. | 4.87 |
| Faeth Therapeutics, Inc. | 26.03 |
| Nuvectis Pharma, Inc. | 21.12 |
| ACADIA Pharmaceuticals, Inc. | 19.78 |
| Alnylam Pharmaceuticals, Inc. | 232.68 |
Price Related Metrics
| PS Ratio | 39.96 |
| Earnings Yield | -29.61% |
| Market Cap | 384.31M |